ClinicalTrials.gg
Not yet recruitingNCT07394543MYOCARDITI-LGEUpdated Feb 6, 2026

French Registry of CMR Late Gadolinium Enhancement in Myocarditis

An observational study in Myocarditis Acute, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-06.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
5,000
Ages
18 Years and older
Sex
All
01

Study summary

Acute myocarditis is a major cause of death in young adults and carries substantial morbidity, including a significant risk of progression to dilated cardiomyopathy. Current diagnostic and therapeutic strategies remain poorly defined, making risk stratification crucial to enable personalized treatments and reduce mortality and major cardiovascular events.

02

Conditions studied

  • Myocarditis Acute

Browse trials for

Keywords

  • Late Gadolinium Enhancement
  • Myocarditis
03

In context

Myocarditis

174 studies on the registry are indexed under Myocarditis; 75 are open to participants now.

This study's planned enrollment of 5,000 is above the median of 208 across 120 observational studies indexed under Myocarditis.

Browse Myocarditis studies →

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,592 studies on the registry; 1,033 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study will include all consecutive patients with AM referred for CMR assessment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years
  2. Ability to provide informed non-opposition
  3. AM diagnosis confirmed using CMR, fulfilling the modified Lake Louise diagnostic criteria

Exclusion criteria

Exclusion Criteria:

1. Patients unable to provide informed non-opposition.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
5,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. All-cause mortality

    All-cause mortality defined using the French national registry of death (INSEE).

    Time frame: From enrollment to the end of follow up at 10 years

Secondary outcomes

  1. All-cause death

    Time frame: From enrollment to the end of follow up at 10 years

  2. Heart transplantation

    Time frame: From enrollment to the end of follow up at 10 years

  3. Ventricular arrhythmia

    Time frame: From enrollment to the end of follow up at 10 years

  4. Hospitalisation for acute heart failure

    Time frame: From enrollment to the end of follow up at 10 years

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07394543
Responsible party
Sponsor
First posted
Feb 6, 2026
Start date
Feb 10, 2026 (estimated)
Primary completion
Feb 10, 2036 (estimated)
Completion
Feb 10, 2036 (estimated)
Last update
Feb 6, 2026

Study contacts

Théo PEZEL, Dr
Contact
theo.pezel@aphp.fr
+33 6 68 72 24 89

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion